Stock ELTX ELICIO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Elicio Therapeutics, Inc.

Equities

ELTX

US28657F1030

End-of-day quote Nasdaq
Other stock markets
 03:30:00 05/06/2024 am IST 		5-day change 1st Jan Change
7.98 USD +5.70% Intraday chart for Elicio Therapeutics, Inc. +4.72% -4.32%
23/05 Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting CI
15/05 Elicio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting
Elicio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Elicio Therapeutics, Inc. to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing Amplify-201 Phase 1 Study of ELI-002 and ElI-008 at the AACR Annual Meeting
Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Elicio Therapeutics, Inc. Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
Elicio Therapeutics Reports First Patient Dosed in Mid-Stage Pancreatic Cancer Trial
Elicio Therapeutics, Inc. Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
Elicio Therapeutics, Inc. Publishes Updated Preliminary Phase 1 Data from AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
Elicio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Elicio Therapeutics, Inc. Announces Resignation of Annette Matthies as Chief Business Officer
Elicio Therapeutics Says Solid Tumor Phase 1 Study of ELI-002 Showed 'Promising' Preliminary Relapse-Free Survival Data
Elicio Therapeutics, Inc. Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of Eli-002 At AACR Special Conference: Pancreatic Cancer
Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Elicio Therapeutics Reports 'Positive' Results From Phase 1 Cancer Immunotherapy Trial; Shares Jump Premarket
Elicio Therapeutics, Inc. Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer
Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.
Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELTX Stock
  4. News Elicio Therapeutics, Inc.
  5. Other languages